Comparison
Lixisenatide vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
320367-13-3
910463-68-2
Molecular weight
4858.5 g/mol
4113.6 g/mol
Half-life
3 h
165 h
Sequence
HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
4
of which in humans
5
3
Effects recorded
3
3
Open conflicts
1
1
Documented adverse events
1
5